Depo-Provera: FDA Adds Brain Tumor Warning to Label

New FDA Warning for Depo-Provera and Meningioma Risk

For many years, Depo-Provera has been a widely used contraceptive option for women. However, recent developments have brought critical safety information to light. In December 2025, the U.S. Food and Drug Administration (FDA) approved a significant update to the prescribing information for Depo-Provera, adding a warning about a potential increased risk of meningioma, a type of brain tumor. This FDA action follows growing medical research and numerous lawsuits alleging that the drug’s manufacturer failed to adequately warn patients and healthcare providers about this serious risk.

Understanding Depo-Provera and Meningiomas

Depo-Provera contains medroxyprogesterone acetate (MPA), a synthetic form of the hormone progesterone, which works to prevent pregnancy. Meningiomas are typically slow-growing tumors that form on the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign (non-cancerous), their growth can lead to severe neurological symptoms depending on their size and location, sometimes requiring surgery or radiation.

The FDA’s Action: A Critical Label Change

The FDA’s decision to update the Depo-Provera label in December 2025 was a pivotal moment for patient safety. The new warning explicitly states that cases of meningioma have been reported following repeated administration of MPA, primarily with long-term use. This label change applies to both FDA-approved injectable formulations of the drug. It advises physicians and clinicians to counsel patients about this potential risk, monitor for signs or symptoms suggestive of meningioma, and consider discontinuing Depo-Provera if a meningioma is diagnosed.

This update by the FDA is particularly significant because, as reported, similar warnings had already appeared on Depo-Provera labels in other countries, including European and Canadian health agencies, for some time before the U.S. label change.

Medical Research Linking Depo-Provera to Meningiomas

The FDA’s label change was influenced by emerging observational data, including a large population-based case-control study published in the British Medical Journal (BMJ). This research reportedly identified an increased risk of intracranial meningioma associated with prolonged use (typically one year or more) of injectable MPA. One study found that prolonged exposure was associated with an approximately 5.6-fold increase in the odds of surgically treated intracranial meningioma. Researchers have noted that women who used Depo-Provera for longer than a year are reportedly over 5 times more likely to develop these tumors.

While studies show an association, researchers have not established direct causation. However, the consistent findings across multiple studies underscore the importance of this new warning for patients and healthcare providers. For more information on medical research, resources like PubMed can be helpful.

Implications for Individuals Who Used Depo-Provera

For many women who used Depo-Provera and subsequently developed a meningioma, the FDA label change may validate their concerns regarding the drug’s safety. The ongoing Depo-Provera lawsuits allege that patients were not adequately warned about these risks, preventing them from making fully informed decisions about their birth control. If you or a loved one used Depo-Provera and were diagnosed with a meningioma, this new information is crucial. You can learn more about the specific legal allegations by visiting our dedicated page on Depo-Provera Meningioma Litigation.

Depo-Provera Litigation Updates

The legal landscape surrounding Depo-Provera and meningioma claims continues to evolve. As of July 2026, thousands of lawsuits have been filed in federal courts, many of which have been consolidated into a multidistrict litigation (MDL) to streamline pretrial proceedings. In June 2026, it was reported that Pfizer, the manufacturer, reached a tentative agreement to resolve a substantial portion of these federal lawsuits. However, it is important to note that this settlement is reportedly not yet final, does not cover every case, and may not affect lawsuits filed in state courts. This development could open a path to potential compensation for many women, though details are still being finalized. For details on how MDLs work, the U.S. Courts website offers comprehensive information.

Recognize the Symptoms of Meningioma

Symptoms of a meningioma can vary widely depending on the tumor’s size and location in the brain or spinal cord. Some common symptoms to be aware of include persistent headaches, seizures, vision changes or loss, weakness, numbness, and memory issues. If you have used Depo-Provera and are experiencing any new or worsening neurological symptoms, it is essential to seek immediate medical attention from a qualified healthcare professional. Further information about meningiomas can be found through resources like the National Cancer Institute.

Take the Next Step

If you or a loved one developed a meningioma after using Depo-Provera, understanding your legal options is crucial. The recent FDA label change and ongoing litigation highlight the importance of seeking legal guidance. Our firm is dedicated to helping individuals affected by such drug injuries. We encourage you to contact us for a confidential and free case review to discuss your specific situation and determine if you may be eligible to pursue a claim. Early action is often important due to legal deadlines that may apply to your case.